PMID- 19650167
OWN - NLM
STAT- MEDLINE
DCOM- 20090917
LR  - 20131121
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 14
IP  - 2
DP  - 2009 Apr-Jun
TI  - Do the time to chemotherapy response and the dose intensity have an impact on 
      patient outcome in advanced non-small cell lung cancer?
PG  - 203-9
AB  - PURPOSE: To better define the importance of early response rate (RR) as well as 
      dose intensity (DI) in advanced non small cell lung cancer (NSCLC) patients 
      treated with platinum-based combination chemotherapy. PATIENTS AND METHODS: 
      Analysed were stage IIIB and IV NSCLC patients included in 4 prospective clinical 
      trials. All of them were treated with cisplatin 120 mg/m2 (the majority of 
      patients) or carboplatin 500 mg/m2, and since 2000 with AUC 5 (the minority of 
      patients) with second-generation platinum-based regimens. Responding patients 
      (complete response/CR and partial response/PR) were divided into 4 different 
      categories, depending on the time when response was first registered. DI and 
      total dose (TD) of cisplatin was calculated for 93 patients with response or 
      stable disease (SD). RESULTS: Among 362 patients analysed, 117 (32%) were 
      responders. Although "early" responders (54 patients after the 2nd cycle, median 
      survival 10 months; 42 patients after the 3rd cycle, median survival 11 months) 
      lived shorter than "late" responders (11 patients after the 4th cycle median 
      survival 12 months; 10 patients after the 5th cycle, median survival 19 months), 
      these differences were not statistically significant, neither in terms of overall 
      survival (OS) nor in time to progression (TTP). DI in patients with CR+PR+SD was 
      30 mg/m2/week (median). TD of cisplatin in CR+PR patients was 577 mg, whereas it 
      was 475 mg in patients with SD (p=0.004). These differences followed significant 
      differences in the number of the cycles received and median survival between 
      CR+PR vs. SD patients. CONCLUSION: Early response was not associated with better 
      survival, DI in SD patients did not differ from responding patients, but 
      responding patients received more cisplatin and lived longer.
FAU - Radosavljevic, D
AU  - Radosavljevic D
AD  - Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, 
      Belgrade, Serbia. davorr@ncrc.ac.rs
FAU - Golubicic, I
AU  - Golubicic I
FAU - Gavrilovic, D
AU  - Gavrilovic D
FAU - Kezic, I
AU  - Kezic I
FAU - Jelic, S
AU  - Jelic S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 50SG953SK6 (Mitomycin)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/secondary
MH  - Cisplatin/administration & dosage
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Mitomycin/administration & dosage
MH  - Neoplasm Recurrence, Local/drug therapy/pathology
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2009/08/04 09:00
MHDA- 2009/09/18 06:00
CRDT- 2009/08/04 09:00
PHST- 2009/08/04 09:00 [entrez]
PHST- 2009/08/04 09:00 [pubmed]
PHST- 2009/09/18 06:00 [medline]
PST - ppublish
SO  - J BUON. 2009 Apr-Jun;14(2):203-9.